Brian A Walker

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. doi request reprint Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
    Brian A Walker
    The Institute of Cancer Research, London, UK
    Blood 117:553-62. 2011
  2. doi request reprint A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
    Brian A Walker
    Section of Haemato oncology, The Institute of Cancer Research, London, UK
    Blood 116:e56-65. 2010
  3. doi request reprint Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival
    Kevin D Boyd
    The Institute of Cancer Research, Haemato Oncology Research Unit, Division of Molecular Pathology, London, United Kingdom
    Clin Cancer Res 17:7776-84. 2011
  4. ncbi request reprint The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy
    Kevin D Boyd
    The Institute of Cancer Research, Section of Haemato oncology, London, United Kingdom
    Genes Chromosomes Cancer 50:765-74. 2011
  5. pmc Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome
    Nicholas J Dickens
    Section of Haemato oncology, The Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 16:1856-64. 2010
  6. doi request reprint XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments
    Tina Bagratuni
    Section of Haemato oncology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
    Blood 116:250-3. 2010
  7. ncbi request reprint Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
    Matthew W Jenner
    Section of Haemato oncology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
    Blood 110:3291-300. 2007
  8. pmc Deletions of CDKN2C in multiple myeloma: biological and clinical implications
    Paola E Leone
    Section of Haemato oncology, The Institute of Cancer Research, 15 Cotswold Road, London, United Kingdom
    Clin Cancer Res 14:6033-41. 2008
  9. doi request reprint Gender disparities in the tumor genetics and clinical outcome of multiple myeloma
    Kevin D Boyd
    The Institute of Cancer Research, Section of Haemato oncology, London, United Kingdom
    Cancer Epidemiol Biomarkers Prev 20:1703-7. 2011
  10. doi request reprint Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma
    David C Johnson
    Institute of Cancer Research, London, UK
    J Clin Oncol 29:797-804. 2011

Collaborators

Detail Information

Publications17

  1. doi request reprint Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
    Brian A Walker
    The Institute of Cancer Research, London, UK
    Blood 117:553-62. 2011
    ..Overall, DNA methylation changes significantly during disease progression and between cytogenetic subgroups...
  2. doi request reprint A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
    Brian A Walker
    Section of Haemato oncology, The Institute of Cancer Research, London, UK
    Blood 116:e56-65. 2010
    ..This study was registered at http://isrctn.org as ISRCTN68454111...
  3. doi request reprint Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival
    Kevin D Boyd
    The Institute of Cancer Research, Haemato Oncology Research Unit, Division of Molecular Pathology, London, United Kingdom
    Clin Cancer Res 17:7776-84. 2011
    ..Regions on 1p with recurrent deletions in presenting myeloma patients were examined with the purpose of defining the deletions and assessing their survival impact...
  4. ncbi request reprint The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy
    Kevin D Boyd
    The Institute of Cancer Research, Section of Haemato oncology, London, United Kingdom
    Genes Chromosomes Cancer 50:765-74. 2011
    ....
  5. pmc Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome
    Nicholas J Dickens
    Section of Haemato oncology, The Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 16:1856-64. 2010
    ..However, these indicators do not capture all prognostic information. Gene expression analysis can be used to identify poor-prognosis patients and this can be improved by combination with information about DNA-level changes...
  6. doi request reprint XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments
    Tina Bagratuni
    Section of Haemato oncology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
    Blood 116:250-3. 2010
    ..This study highlights the importance of XBP1 in myeloma and its significance as an independent prognostic marker and as a predictor of thalidomide response...
  7. ncbi request reprint Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma
    Matthew W Jenner
    Section of Haemato oncology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
    Blood 110:3291-300. 2007
    ..These 2 genes and their corresponding pathways provide an important insight into the potential mechanisms by which 16q LOH confers poor prognosis...
  8. pmc Deletions of CDKN2C in multiple myeloma: biological and clinical implications
    Paola E Leone
    Section of Haemato oncology, The Institute of Cancer Research, 15 Cotswold Road, London, United Kingdom
    Clin Cancer Res 14:6033-41. 2008
    ..3 has been identified in myeloma cell lines as the potential target of the deletion. We tested the clinical impact of 1p deletion and used high-resolution techniques to define the role of CDKN2C in primary patient material...
  9. doi request reprint Gender disparities in the tumor genetics and clinical outcome of multiple myeloma
    Kevin D Boyd
    The Institute of Cancer Research, Section of Haemato oncology, London, United Kingdom
    Cancer Epidemiol Biomarkers Prev 20:1703-7. 2011
    ..Several cancer types have differences in incidence and clinical outcome dependent on gender, but these are not well described in myeloma. The aim of this study was to characterize gender disparities in myeloma...
  10. doi request reprint Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma
    David C Johnson
    Institute of Cancer Research, London, UK
    J Clin Oncol 29:797-804. 2011
    ..To indentify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN)...
  11. doi request reprint Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells
    Brian A Walker
    Molecular Haematology, Haemato Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK
    Blood 121:3413-9. 2013
    ....
  12. doi request reprint Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
    Brian A Walker
    Haemato Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK
    Blood 120:1077-86. 2012
    ..These results are consistent with a distinct molecular pathogenesis underlying each subgroup and have important impacts on targeted treatment strategies. The Medical Research Council Myeloma IX trial is registered under ISRCTN68454111...
  13. ncbi request reprint Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma
    Brian A Walker
    Section of Haemato oncology, Institute of Cancer Research, Surrey, UK
    Clin Lymphoma Myeloma 7:186-91. 2006
    ..In this review, we discuss the benefits of SNP-based arrays along with some of the drawbacks and how that data can be used in conjunction with expression data to identify genes with altered expression in regions of interest...
  14. doi request reprint Improved risk stratification in myeloma using a microRNA-based classifier
    Ping Wu
    Section of Haemato oncology, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Haematol 162:348-59. 2013
    ..This is the first report showing that miRNAs can be built into molecular diagnostic strategies for risk stratification in MM...
  15. doi request reprint Identification of a novel t(7;14) translocation in multiple myeloma resulting in overexpression of EGFR
    Brian A Walker
    Molecular Haematology, Haemato Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK
    Genes Chromosomes Cancer 52:817-22. 2013
    ..This case represents a rare and novel translocation in myeloma, from which a targeted personalized treatment, in the form of EGFR inhibitors, which are commonly used in other cancer types, could be used...
  16. pmc A modified method for whole exome resequencing from minimal amounts of starting DNA
    Iwanka Kozarewa
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 7:e32617. 2012
    ..This method, which can be performed in most laboratories using commonly available reagents, has the potential to enhance large scale profiling efforts such as the resequencing of tumour exomes...
  17. doi request reprint The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma
    Luca Agnelli
    Department of Medical Sciences, University of Milan and Hematology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Italy
    Clin Cancer Res 17:7402-12. 2011
    ....